当前位置:首页 - 行情中心 - 山东药玻(600529) - 财务分析 - 利润表

山东药玻

(600529)

  

流通市值:122.30亿  总市值:122.30亿
流通股本:6.64亿   总股本:6.64亿

利润表

报告期2026-06-302026-03-312025-12-312025-09-30
公司类型通用通用通用通用
一、营业总收入2,280,395,300.461,219,063,985.044,474,018,978.753,352,070,071.23
  营业收入2,280,395,300.461,219,063,985.044,474,018,978.753,352,070,071.23
二、营业总成本1,815,722,108.72960,424,944.763,533,710,798.92,658,703,139.69
  营业成本1,530,906,053.34822,101,029.112,983,735,053.332,227,231,212.57
  税金及附加32,149,538.1815,842,271.9251,340,606.3637,676,460.66
  销售费用53,892,998.4629,277,954.15107,683,043.9377,801,911.18
  管理费用112,759,285.6251,384,369.95232,409,811.05194,166,835.56
  研发费用74,976,290.8836,717,625.5174,795,365.98138,496,841.02
  财务费用11,037,942.245,101,694.13-16,253,081.75-16,670,121.3
  其中:利息费用594,559.02706,059.83514,193.2118,210.41
  其中:利息收入7,891,784.33,868,752.3812,852,652.0311,705,229.47
三、其他经营收益
  加:公允价值变动收益4,381,715.522,138,682.519,136,242.467,987,785.22
  加:投资收益9,582,895.864,664,897.4917,548,332.4413,355,985.71
  资产处置收益2,495,584.8737,608.291,452,467.75808,971.47
  资产减值损失(新)-33,853,345.47-18,152,583.1-156,894,172.13-80,911,051.13
  信用减值损失(新)-2,196,502.03-10,627,038.123,946,360.61-74,651.04
  其他收益10,900,843.885,093,497.2322,463,415.9617,332,606.13
四、营业利润455,984,384.37241,794,104.58837,960,826.94651,866,577.9
  加:营业外收入3,370,641.5260,330.192,349,125.791,777,673.44
  减:营业外支出6,999,837.792,824,946.999,481,883.945,252,955.54
五、利润总额452,355,188.08239,229,487.78830,828,068.79648,391,295.8
  减:所得税费用81,487,236.4238,023,467.65141,202,028.13105,937,637.43
六、净利润370,867,951.66201,206,020.13689,626,040.66542,453,658.37
(一)按经营持续性分类
  持续经营净利润370,867,951.66201,206,020.13689,626,040.66542,453,658.37
(二)按所有权归属分类
  归属于母公司股东的净利润370,867,951.66201,206,020.13689,626,040.66542,453,658.37
  扣除非经常损益后的净利润354,428,900.51194,124,328.97658,460,201.17515,879,178.99
七、每股收益
  (一)基本每股收益0.560.31.040.82
  (二)稀释每股收益0.560.31.040.82
九、综合收益总额370,867,951.66201,206,020.13689,626,040.66542,453,658.37
  归属于母公司股东的综合收益总额370,867,951.66201,206,020.13689,626,040.66542,453,658.37
公告日期2026-08-252026-04-252026-03-072025-10-28
审计意见(境内)标准无保留意见
TOP↑